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Letters to the EditorMETHYLENE BLUE IN
PATIENTS WITH SEVERE
PULMONARY HYPERTENSION
To the Editor:
We read with great interest the re-
cent article by Grubb and colleagues.1
Apart from the successful reversal of
postcardiopulmonary bypass vasople-
gia with the use of a single dose
(1 mg/kg) followed by continuous in-
fusion of 0.5 mg/kg/hour intravenous
methylene blue, achieving hemody-
namic stability during a third-time
redo sternotomy for heart transplanta-
tion in a 60-year-old man, the authors
reported the role of methylene blue
as a causative agent of serotonin
syndrome in a patient receiving
selective serotonin reuptake inhibitor
medication.
We entirely agreewith their opinion
and would like to add a brief comment
related to our experience in the treat-
ment of anaphylaxis secondary to
protamine administration after cardiac
surgery. The patient was a 70-year-old
woman undergoing aortic valve re-
placement for severe aortic stenosis
with moderated left ventricular dys-
function and normal pulmonary
pressure. Her past medical history in-
cluded hypertension and smoking (10
pack-years) and she denied having al-
lergy to fish proteins. Her medications
included furosemide and enalapril.
The operation was carried out through
a median sternotomy with antegrade
cold blood cardioplegia. Operative
findings revealed a small, heavily cal-
cified aortic annulus. After extensive
decalcification a No. 19 bioprosthesis
(Mitroflow; Sorin Group Inc, Van-
couver, Canada) was implanted. The
weaning from cardiopulmonary by-
pass was uneventful with a low dose
of vasoconstrictor support. Protamine
infusion was accompanied by re-
fractory hypotension, despite the
use of high doses of epinephrine
and norepinephrine. The administra-
tion of 1% methylene blue (2 mg/kg
during a time period of 20 minutes)
and the discontinuation of protamine898 The Journal of Thoracic and Cwere highly effective to restore
a normal hemodynamic status, and
to taper down progressively the
vasoconstrictor agents. The postop-
erative course was unremarkable.
According to the literature, this is
the third report describing the suc-
cessful use of methylene blue in
dramatic anaphylaxis secondary to
protamine administration after car-
diac surgery.2,3
We have only 1 question for Grubb
and colleagues, who apparently have
bigger experience with methylene
blue in vasoplegic syndrome. What is
your opinion about infusingmethylene
blue in patients with known severe
pulmonary hypertension undergoing
cardiac surgery and experiencing
catecholamine-refractory vasoplegic
syndrome? In vitro and in vivo studies
suggest that resting pulmonary vascu-
lar tone and endothelium-dependent
pulmonaryvasodilatation aremediated
by changes in vascular smooth muscle
concentrations of cyclic guanosine
30,50 monophosphate.3,4 Methylene
blue is a potent guanylate cyclase
inhibitor. And by reducing the effect
ofnitricoxide5 it cancausea significant
increase in pulmonary arterial pres-
sure, especially in patients with severe
pulmonary hypertension and cause
a detrimental effect on gas exchange.
We congratulate Grubb and col-
leagues on the survival of their patient
and the dissemination of important in-
formation concerning the caution of
using methylene blue in patients
with vasoplegic syndrome who are re-
ceiving antidepressant therapy; more-
over, we want to add a warning
against the use of methylene blue in
patients with severe pulmonary
hypertension.
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Hajj-Chahine and colleagues1 de-
scribean interestingcaseofaprotamine
reaction resulting in hypotension unre-
sponsive to vasopressor therapy. Meth-
ylene blue 1%, dosed 2 mg/kg during
a period of 20 minutes, resulted in nor-
mal hemodynamics. The case high-
lights yet another example of the use
of methylene blue for the treatment of
vasoplegic syndrome.
In regard to Hajj-Chahine and col-
leagues’ inquiry, in patients with known
severe pulmonary hypertension (PH)
and vasoplegic syndrome undergoing
cardiac surgery, there is certainly con-
cern for worsening PH due to a reduc-
tion of endogenous nitric oxide with
the potential for right ventricular failure.
We have not had this experience, al-
though we are aware of the possibility.
We certainly would caution against
using methylene blue in patients with
severe PH.
The comments regarding the use
of methylene blue for the treatment
of vasoplegia offered by Evora2 are
appreciated. We agree, methylene
blue clearly can be beneficial for
Letters to the Editorselect patients. The issue of seroto-
nin syndrome is rare, usually self-
limiting, and should not deter us
from using methylene blue to coun-
teract vasoplegia. We are in the pro-
cess of analyzing and summarizing
our results after implementation of
a methylene blue protocol in cardiac
transplantation.The JournalKendra J. Grubb, MD, MHA
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